Synergy Pharmaceuticals, Inc Common Stock
SGYP
SGYP was delisted on the 7th of March, 2019.
149 hedge funds and large institutions have $1.58B invested in Synergy Pharmaceuticals, Inc Common Stock in 2016 Q3 according to their latest regulatory filings, with 30 funds opening new positions, 53 increasing their positions, 32 reducing their positions, and 14 closing their positions.
309% more capital invested
Capital invested by funds: $386M → $1.58B (+$1.19B)
124% more call options, than puts
Call options by funds: $9.5M | Put options by funds: $4.24M
114% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 14
66% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 32
11% more funds holding
Funds holding: 134 → 149 (+15)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$7.47M |
| 2 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$3.77M |
| 3 |
Morgan Stanley
New York
|
+$3.43M |
| 4 |
EI
EAM Investors
Solana Beach,
California
|
+$2.47M |
| 5 |
FI
Fosun International
Hong Kong,
China
|
+$2.37M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PC
Paulson & Co
New York
|
-$16.5M |
| 2 |
Invesco
Atlanta,
Georgia
|
-$6.35M |
| 3 |
SG Americas Securities
New York
|
-$5.65M |
| 4 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$5.47M |
| 5 |
Millennium Management
New York
|
-$4.53M |
SGYP Hedge Fund Activity: Q3 2016 in Review
149 of the 3,759 institutional investors tracked by Wall St. Rank reported a position in Synergy Pharmaceuticals, Inc Common Stock (SGYP) for Q3 2016, worth a combined $1.58B — up 309% from $386M a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new SGYP positions and 14 closed out — a net gain of 16 holders — while 53 added to existing stakes and 32 trimmed.
The largest buyer was Fidelity Investments, opening a new position worth an estimated $7.47M. The largest seller was Paulson & Co, cutting an estimated $16.5M.
- 149 institutional investors held Synergy Pharmaceuticals, Inc Common Stock (SGYP) as of Q3 2016, up from 134 in Q2 2016.
- Funds reported $1.58B of Synergy Pharmaceuticals, Inc Common Stock stock for Q3 2016, up 309% quarter-over-quarter.
- 30 funds opened new Synergy Pharmaceuticals, Inc Common Stock positions in Q3 2016 and 14 closed out, a net change of +16 holders.
- The largest Synergy Pharmaceuticals, Inc Common Stock buyer in Q3 2016 was Fidelity Investments, an estimated $7.47M added.
- The largest Synergy Pharmaceuticals, Inc Common Stock seller in Q3 2016 was Paulson & Co, an estimated $16.5M sold.
Based on aggregated 13F filings for Q3 2016.